Humira Alternatives Compared
| Humira (adalimumab) | Stelara (ustekinumab) | Skyrizi (risankizumab) |
|
|---|
| Humira (adalimumab) | Stelara (ustekinumab) | Skyrizi (risankizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Related suggestions Ulcerative Colitis
|
|||||||||||||||||||||||
| More about Humira (adalimumab) | More about Stelara (ustekinumab) | More about Skyrizi (risankizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Humira has an average rating of 6.4 out of 10 from a total of 699 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 31% reported a negative effect. |
Stelara has an average rating of 7.6 out of 10 from a total of 252 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 15% reported a negative effect. |
Skyrizi has an average rating of 8.0 out of 10 from a total of 58 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Humira side effects |
View all Stelara side effects |
View all Skyrizi side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Humira prices |
View all Stelara prices |
View all Skyrizi prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
480 hours |
1291.2 hours |
672 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 552 drugs are known to interact with Humira:
|
A total of 537 drugs are known to interact with Stelara:
|
A total of 187 drugs are known to interact with Skyrizi:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 31, 2002 |
September 25, 2009 |
April 23, 2019 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Ilumya
Ilumya (tildrakizumab) is used to treat moderate-to-severe plaque psoriasis to reduce plaques ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Vtama
Vtama (tapinarof) is a steroid-free, once-daily cream used to treat plaque psoriasis and atopic ...
Celebrex
Celebrex is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation. Learn about ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.